Researchers from the Germans Trias i Pujol Research Institute (IGTP) have made progress in exploring potential treatments for skin tumours associated with neurofibromatosis type 1. Their findings in ...

Please provide your email address to receive an email when new articles are posted on . Small cNFs were successfully reduced with four different nonsurgical treatment modalities. Deoxycholate and ...

In the opinion of R. Rox Anderson, MD, patients with neurofibromatosis type 1 (NF1) have long been underserved in the medical field. Affected children are born with café-au-lait spots and sometimes ...

BOSTON, Nov. 13, 2023 /PRNewswire/ -- NFlection Therapeutics Inc., a company developing topical MEK inhibitors for RAS-mediated skin conditions, today announced positive topline results from a ...

Please provide your email address to receive an email when new articles are posted on . Quality of life impairment was most associated with facial involvement and the number of neurofibromas.

UCLA researchers developed a new method to study NF1, accelerating the search for potential treatments. Future work is supported by $1.6 million in grants from the Neurofibromatosis Therapeutics ...

This month, our discussion focuses on the clinical management of plexiform neurofibromas in the era of selumetinib, a MEK inhibitor medication that was approved by the FDA in 2020 for the treatment of ...